History
Lapatinib in the Treatment of HER2-Positive Breast Cancer Patients
Date of publication: May 31, 2021 Evidence Summary: https://drive.google.com/file/d/1VH5tkZyZr9sGWERXk8eXOyIQno456ixT/view Advisory on non-inclusion in PNF: https://drive.google.com/file/d/19PKRWWZ70bKUJBBuKyXnUjCtK01tzEgL/view (Proponents may submit appeals to hta@doh.gov.ph until 14 June 2021.) HTAC Recommendation Review:
Potassium Citrate [1620 mg (15 mEq)] Tablet
SOH approves the HTAC recommendation on the minor inclusion of an additional dosage strength of potassium citrate [1620 mg (15mEq)] tablet for severe hypocitraturia and recurrent kidney stones in the Philippine National Formulary (PNF) The Secretary of Health (SOH) approved the Health Technology Assessment Council (HTAC) recommendation on the minor inclusion of an additional dosage continue reading : Potassium Citrate [1620 mg (15 mEq)] Tablet
Vasopressin 20 I.U./mL (I.V./I.M./S.C.)
The Secretary of Health (SOH) approved the HTAC recommendation on the reinclusion of vasopressin in the PNF on 02 March 2022. Link to issuance Vasopressin 20 I.U./mL (I.V./I.M./S.C.) was previously listed in the Philippine National Formulary (PNF); however, it was automatically delisted in 2017 since the drug was no longer registered in the Philippine Food continue reading : Vasopressin 20 I.U./mL (I.V./I.M./S.C.)
Abiraterone acetate [250 mg tablet] in combination with prednisone as first-line or second-line treatment of metastatic castration-resistant prostate cancer (mCRPC)
HTA Council Recommendation (as of 23 November 2022) The HTA Council recommends the government financing of abiraterone acetate (250mg tablet) in combination with prednisone (PD) as first-line treatment or second-line treatment for metastatic castration-resistant prostate cancer (mCRPC) through its inclusion in the Philippine National Formulary. Relevant Information Evidence and Relevant Documents Assessment History Back to continue reading : Abiraterone acetate [250 mg tablet] in combination with prednisone as first-line or second-line treatment of metastatic castration-resistant prostate cancer (mCRPC)